<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="17698">Chloramphenicol</z:chebi> (CAP) is an antibiotic which has been implicated in the etiology of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> in man </plain></SENT>
<SENT sid="1" pm="."><plain>This product is also used in veterinary medicine </plain></SENT>
<SENT sid="2" pm="."><plain>The medical use of <z:chebi fb="0" ids="17698">chloramphenicol</z:chebi> has been limited to cases where the drug is indispensible but veterinary use may lead to the presence of residues in the meat of treated animals and it is essential to establish acceptable levels of intake of such residues in order to protect human health </plain></SENT>
<SENT sid="3" pm="."><plain>CAP is metabolized into at least 6 metabolites: <z:chebi fb="0" ids="35801">nitroso</z:chebi>-CAP (NO-CAP), formed in the liver, 3 excretion products: the <z:chebi fb="0" ids="24302">glucuronide</z:chebi> (CAP-G), the CAP base (NAPD), and an alcoholic derivative, HAP </plain></SENT>
<SENT sid="4" pm="."><plain>Dehydro-CAP (DH-CAP) and the dehydro-CAP base (NPAP) are formed by enterobacteria in the large bowel </plain></SENT>
<SENT sid="5" pm="."><plain>The objective of the present study was to investigate (1) the cytotoxicity of CAP and its metabolites and (2) their ability to induce DNA damage in human cells </plain></SENT>
<SENT sid="6" pm="."><plain>This work was performed with human peripheral blood lymphocytes (PBL) and with a <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell line (Raji) </plain></SENT>
</text></document>